Updates to the Australian Pharmaceutical Benefits Scheme
22 May 2023
Update
Services Australia has published a release detailing new and amended listings of medications on the Australian Pharmaceutical Benefits Scheme (PBS), effective from 1 May 2023.
Amendments have been made to a range of medications on the PBS, including the following medications:
- Methylphenidate (Ritalin® LA) being amended to allow access for adults with a retrospective diagnosis of ADHD. This includes access to capsules containing methylphenidate hydrochloride 10 mg, 20 mg, 30 mg, 40 mg, 60mg (modified release).
- Naltrexone (Naltrexone GH®) having a reduction in authority level for the treatment of alcohol dependence.
Enquiries regarding new and amended listings can be directed to the PBS at pbs@health.gov.au.
More news & views
![](/kenticoimage.axd/media/66fb73b2-cc6a-4319-a5e1-f9b4947c0b99/Elizabeth-Moore-Board.jpg?width=200&height=200&quality=90&rmode=crop&d=110915&hmac=3c782573a006d1bf865f69ddbc9ea373c3e284792627117879b1e3f36fcacb51)
President's Column June 2024
An update from the RANZCP President, Dr Elizabeth Moore on College activities, achievements and news...
24 June 2024
Applications open for Certificate of Postgraduate Training in Clinical Psychiatry
Fellows who would like to be involved in supervising and assessing Certificate participants are invi...
![](/kenticoimage.axd/media/19208b10-4cf2-476f-8ea5-1453d5e01b1d/pif-group-photo.png?width=600&height=400&quality=90&rmode=crop&d=023143&hmac=05d8d20296696ae5c61f13d8198502ad5bf6caaaa5b9abfeb9c6ade6b00e98b2)
Psychiatry Interest Forum (PIF) program at 2024 Congress
PIF sponsored medical students and junior doctors reflect on their experience at the RANZCP 2024 Con...